By Aphios Corp.
A New Standard in Mental Health Innovation The Anxiety Epidemic Anxiety disorders are the most common mental health condition worldwide, affecting nearly 1 in 5 American adults and 1 in 3 adolescents each year. The COVID-19 pandemic has intensified this crisis, driving a 25% global increase in anxiety and depression. Current treatments—such as antidepressants and benzodiazepines—offer limited relief, often come with adverse side effects, and are only effective in 40–60% of patients. The Promise of Cannabidiol (CBD) CBD, a non-psychoactive component of Cannabis sativa, has demonstrated powerful anxiolytic effects in both preclinical and clinical studies. It interacts with serotonin (5-HT1A) and cannabinoid (CB1) receptors to regulate fear and anxiety behaviors. However, conventional oral CBD has very low bioavailability (~6%) and requires large doses for therapeutic benefit. Our Innovation: Extended-Release Nano-CBD Aphios Pharma is developing a once-daily, extended-release CBD capsule using our patented SuperFluids™ Polymer Nanospheres (SFS-PNS™) technology. This nanotechnology encapsulates CBD in biodegradable polymer spheres, protecting it from stomach acid and liver metabolism, while enabling controlled release and improved absorption in the gut. Key Advantages - 5x Higher Bioavailability: Delivers more active CBD to the bloodstream - Reduced Dose: From 400–800 mg/day to just 80–160 mg/day - Lower Cost: ~2.5x savings for patients over current oil-based CBD products - No Toxic Solvents: Uses supercritical fluids, not hazardous organics - Enhanced Stability & Sterility: SFS-PNS™ ensures clean, scalable production Better Science. Better CBD. Unlike standard formulations, our SFS-PNS™ process avoids toxic solvent residues and produces sterile, stable nanoparticles. It has been successfully applied to Δ9-THC, insulin, and other difficult-to-deliver drugs. This next-generation CBD formulation is designed to enhance patient adherence, reduce side effects, and offer real relief—naturally. A Once-Daily Solution for Chronic Anxiety With a single daily capsule, patients can experience sustained anxiety relief without the sedation, dependency, or tolerance associated with traditional anti-anxiety medications. Our product is designed for those seeking a safer, more effective path to emotional well-being. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Join Us in Transforming Mental Health Aphios Pharma is leading the charge in natural, nanotech-enabled therapeutics. Our CBD innovation represents a scalable, environmentally responsible approach to anxiety treatment with broad potential across CNS disorders.
Consisting of an HIV strain, inactivated by three orthogonal methods: a genetic method to attenuate the virus, a physical method called CFI and a chemical method called AT-2 Our therapeutic HIV/AIDS vaccine consists of an inactivated a strain of HIV, inactivated by three orthogonal methods: a genetic method to attenuate the virus, a physical method called CFI and a chemical method called AT-2. These methods inactivate HIV without causing major structural and physical damage to the virion, including gp120. Such a vaccine preparation should induce both humoral and cellular immune responses. We expect the inactivated attenuated virion to behave similarly to live HIV, with the exception of integration and replication. Thus, the inactivated attenuated virion will bind to and be taken up by dendritic cells and macrophages, which will then present antigens to CD4+ and CD8+ T cells for the generation of T cell help and cytotoxic T cells. Previous experiments in chimpanzees showed that good humoral and cellular responses could be induced with an inactivated, whole HIV immunogen. A more recent study showed induction of humoral and cellular responses with virus-like particles. Finally, both humoral and cellular responses were generated after immunization with AT-2 inactivated SIV. Partnering Opportunity We are seeking global partnerships for developing an HIV therapeutic vaccine that could lead to a functional cure for HIV/AIDS patients. Learn more
CATEGORY
We will also provide research-scale units to biotechnology companies, universities and research institutions to complement and improve your research and development activities.
CATEGORY
Taxanes from Yew Aphios produces natural paclitaxel from the needles of the American and Canadian yew (Taxus media, Taxus canadensis), along with cephalomannine and the paclitaxel intermediates 10-DAB and 9-DHAB. All are isolated with SuperFluids™ CXP technology at 98 to 99% purity. Generic Name: 10-deacetylbaccatin III (10-DAB) Catalog Number: APH-93083 Molecular Formula: C 29 H 36 O 10 Molecular Weight: 544.60 Source: Taxus media "hicksii" or Taxus canadensis
CATEGORY
Taxanes from Yew Aphios produces natural paclitaxel from the needles of the American and Canadian yew (Taxus media, Taxus canadensis), along with cephalomannine and the paclitaxel intermediates 10-DAB and 9-DHAB. All are isolated with SuperFluids™ CXP technology at 98 to 99% purity. Generic Name: Cephalomannine Catalog Number: APH-93082 Molecular Formula: C 45 H 53 NO 14 Molecular Weight: 831.91 Source: Taxus media "hicksii" or Taxus canadensis
CATEGORY
